knowledge -WSS

knowledge

author：leisure time 2025-09-27 10:01:43 - browse：482

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

leisure time

WSS

As digital health tech proliferates, a new institute aims to cut through hype

Pfizer, Moderna say biotech, pharma drug development is a sprint

Pregnancy ages women, but effects reverse after delivery

Doctors find melanoma drugs effective against rare brain cancer

Readout LOUD podcast, live from the STAT Breakthrough Summit East

U.K. officials, researchers try to ease path for bespoke genetic treatments

hotspot

knowledge

explore

Continuity nursing helped my family in our darkest PICU moments

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Google and Epic fight stronger regulation of AI in health care

Anesthesiologist group: stop taking Ozempic before surgery

Key House panel plots a new health care package

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Adam's Take: Intra

Walensky prepares to leave CDC — and Congress — behind

AI can’t replace a physician’s gut feeling

focus

Testing GLP

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Biotech investment managers search for lucrative opportunities

'Patient friction coefficient' can gauge a clinical trial's patient burden

Medicare has a new plan to address drug shortages

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

focus

leisure time

entertainment

hotspot